Business News • PR NewsWire • PharmaEngine Announces Taiwan FDA Granting the Product License of ONIVYDE™ (Irinotecan Liposome Injection) for the Treatment of Metastatic Pancreatic Cancer

PharmaEngine Announces Taiwan FDA Granting the Product License of ONIVYDE™ (Irinotecan Liposome Injection) for the Treatment of Metastatic Pancreatic Cancer

PharmaEngine Announces Taiwan FDA Granting the Product License of ONIVYDE™ (Irinotecan Liposome Injection) for the Treatment of Metastatic Pancreatic Cancer

TAIPEI, Taiwan, March 5, 2016 /PRNewswire/ -- PharmaEngine, Inc. (TWO: 4162) announced that TFDA (Taiwan Food and Drug Administration) approved the product license of ONIVYDE™ (irinotecan liposome injection, nal-IRI). ONIVYDE is indicated, in combination with fluorouracil (5-FU) and...

View More : http://www.prnewswire.com/news-releases/pharmaengine-announces-taiwan-fda-granting-the-product-license-of-onivyde-irinot...

Releted News by prnewswire

Virgin America To Present At The J.P. Morgan Aviation, Transportation And Industrials Conference

U.S. Census Bureau Daily Feature for March 5: Help From City Hall

Douglas Crawford Leaves University Role in QB3 Ecosystem